Report of Foreign Issuer (6-k)
May 24 2019 - 1:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2019
Commission File Number: 001-38104
IMMURON LIMITED
|
(Name of Registrant)
|
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia 3053
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒
Form
40-F
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
☐
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐
No
☒
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-
EXPLANATORY
NOTE
On May 23, 2019, Immuron Limited (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity, a division of Fordham Financial
Management, Inc., as representative of the several underwriters listed therein (the “Underwriters”), with respect to
the issuance and sale in an underwritten public offering (the “Offering”) by the Company of an aggregate of 500,000
American Depository Shares (“ADSs”) at a public offering price of $4.00 per ADS. Each ADS represents 40 ordinary shares,
no par value per share.
Pursuant to the Underwriting Agreement,
the Company granted the Underwriters a 45-day option to purchase up to an additional 75,000 ADSs, solely to cover over-allotments,
if any.
The Underwriting Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the
Company and the Underwriters and termination provisions.
The Offering is expected to close on May
29, 2019, subject to the satisfaction of customary closing conditions.
The estimated gross proceeds to the Company
are expected to be approximately $2,000,000 prior to deducting underwriting discounts, commissions and other estimated offering
expenses. The Company intends to use the net proceeds from the offering to support its clinical trials and its non-clinical, manufacturing
and regulatory activities as well as for working capital and general corporate purposes.
The foregoing description of the Underwriting
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement,
which is filed as Exhibit 1.1 hereto is incorporated herein by reference.
The ADSs are offered by the Company pursuant
to a registration statement on Form F-3 (File No. 333-230762) filed with the Securities and Exchange Commission (the “Commission”),
which was declared effective by the Commission on April 17, 2019.
On May 23, 2019, the Company issued a press
release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 hereto. Exhibit 99.1 shall
not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended and shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.
The legal opinion of Francis Abourizk Lightowlers,
Australian counsel to the Company, relating to the legality of the issuance and sale of the ADSs is filed as Exhibit 5.1 hereto.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
IMMURON LIMITED
|
|
|
Date: May 24, 2019
|
By:
|
/s/ Gary S. Jacob
|
|
|
Gary S. Jacob
|
|
|
Chief Executive Officer
|
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024